Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Oncimmune Holdings PLC - Nottingham-based immunodiagnostics developer - Appoints Alistair MacDonald as new chair as now ex-chair Meinhard Schmidt retires from the board. Firm adds it has a pipeline of potential contracts. ‘I am delighted to be handing over the reins to Alistair with his wealth of experience in growing pharma services business,’ says Schmidt.
New chair, Macdonald, comments: ‘Oncimmune has successfully delivered on its strategy to transform the business from one wholly focussed on a single asset diagnostic to an emerging pharma services business; the foundation stone is now laid for growth.’
Current Oncimmune stock price: 79.00 pence, down 3.7% on Friday
12-month change: down 55%
Copyright 2022 Alliance News Limited. All Rights Reserved.